

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Aug-2023
Document Type: USP Monographs
DocId: GUID-01883BEE-8063-4955-AAC3-78B37FBA8EC6_2_en-US
DOI: https://doi.org/10.31003/USPNF_M5591_02_01
DOI Ref: u4dd1

© 2025 USPC
Do not distribute

Add the following:

^Sildenafil Injection

DEFINITION

Sildenafil Injection is a sterile solution of Sildenafil Citrate in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of sildenafil ($C_{22}H_{30}N_6O_4S$). It also contains dextrose.

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Solution A: 15.4 g/L of [ammonium acetate](#) in [water](#)

Mobile phase: [Acetonitrile](#) and *Solution A* (50:50)

Standard solution: 0.11 mg/mL of [USP Sildenafil Citrate RS](#) in *Mobile phase*. Sonicate to dissolve if necessary.

Sample solution: Nominally 0.08 mg/mL of sildenafil prepared as follows. Transfer 5 mL of *Injection* to a 50-mL volumetric flask and dilute with *Mobile phase* to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 245 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 15-cm; 5-μm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 20 μL

Run time: NLT 1.6 times the retention time of sildenafil

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sildenafil ($C_{22}H_{30}N_6O_4S$) in the portion of *Injection* taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of sildenafil from the *Sample solution*

r_S = peak response of sildenafil from the *Standard solution*

C_S = concentration of [USP Sildenafil Citrate RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of sildenafil in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of sildenafil, 474.58

M_{r2} = molecular weight of sildenafil citrate, 666.70

IMPURITIES• **ORGANIC IMPURITIES****Dilute phosphoric acid:** 10% (v/v) [phosphoric acid](#) in [water](#)**Buffer:** 3.5 g/L of [potassium phosphate, dibasic](#) in [water](#). Adjust with *Dilute phosphoric acid* to a pH of 7.0.**Solution A:** [Acetonitrile](#) and *Buffer* (14:86)**Solution B:** [Acetonitrile](#) and *Buffer* (74:26)**Mobile phase:** See [Table 1](#).**Table 1**

Time (min)	Solution A (%)	Solution B (%)
0	78	22
5	78	22
20	50	50
30	40	60
35	78	22
40	78	22

Diluent: [Methanol](#) and [water](#) (50:50)**Standard stock solution:** 0.46 mg/mL of [USP Sildenafil Citrate RS](#) in [methanol](#). Sonicate to dissolve if necessary.**Standard solution:** 1.15 µg/mL of [USP Sildenafil Citrate RS](#) from the *Standard stock solution* in *Diluent***Sensitivity solution:** 0.575 µg/mL of [USP Sildenafil Citrate RS](#) from the *Standard solution* in *Diluent***Sample solution:** Nominally 0.4 mg/mL of sildenafil prepared as follows. Transfer 5 mL of *Injection* to a 10-mL volumetric flask and dilute with [methanol](#) to volume.**Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 240 nm**Column:** 4.6-mm × 15-cm; 5-µm packing [L1](#)**Column temperature:** 30°**Flow rate:** 1 mL/min**Injection volume:** 20 µL**System suitability****Samples:** *Standard solution* and *Sensitivity solution***Suitability requirements****Tailing factor:** NMT 2.0, *Standard solution***Relative standard deviation:** NMT 5.0%, *Standard solution***Signal-to-noise ratio:** NLT 10, *Sensitivity solution***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of sildenafil *N*-oxide and any unspecified degradation product in the portion of *Injection* taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/F) \times 100$$

 r_U = peak response of each degradation product from the *Sample solution* r_S = peak response of sildenafil from the *Standard solution* C_S = concentration of [USP Sildenafil Citrate RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of sildenafil in the *Sample solution* (mg/mL) M_{r1} = molecular weight of sildenafil, 474.58 M_{r2} = molecular weight of sildenafil citrate, 666.70 F = relative response factor (see [Table 2](#))**Acceptance criteria:** See [Table 2](#). The reporting threshold is 0.1%.**Table 2**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Sildenafil N-oxide ^a	0.44	0.95	0.2
Sildenafil	1.0	—	—
Any unspecified degradation product	—	1.00	0.2
Total degradation products	—	—	0.5

^a 4-[(4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)phenyl)sulfonyl]-1-methylpiperazine 1-oxide.**SPECIFIC TESTS**

- [pH \(791\)](#): 3.5–4.5
- [PARTICULATE MATTER IN INJECTIONS \(788\)](#): Meets the requirements
- [STERILITY TESTS \(71\)](#): Meets the requirements
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): Meets the requirements

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose glass containers. Store at controlled room temperature.

[• USP REFERENCE STANDARDS \(11\)](#)[USP 5-Hydroxymethylfurfural RS](#)

5-(Hydroxymethyl)furan-2-carbaldehyde.

 $C_6H_6O_3$ 126.11[USP Sildenafil Citrate RS](#)▲ (USP 1-Aug-2023)Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
SILDENAFIL INJECTION	Documentary Standards Support	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 47(6)

Current DocID: GUID-01883BEE-8063-4955-AAC3-78B37FBA8EC6_2_en-US**DOI: https://doi.org/10.31003/USPNF_M5591_02_01****DOI ref: [u4dd1](#)**